5-(1-(3-(methoxymethyl)-3-(3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carbonyl)pyrrolidin-1-yl)ethyl)-3-methylbenzo[d]oxazol-2(3H)-one | 1161427-98-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 5-(1-(3-(methoxymethyl)-3-(3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carbonyl)pyrrolidin-1-yl)ethyl)-3-methylbenzo[d]oxazol-2(3H)-one
• 英文别名: 5-[1-[3-(methoxymethyl)-3-[3-(trifluoromethyl)-7,8-dihydro-5H-1,6-naphthyridine-6-carbonyl]pyrrolidin-1-yl]ethyl]-3-methyl-1,3-benzoxazol-2-one
• CAS: 1161427-98-0
• 化学式: C₂₆H₂₉F₃N₄O₄
• 分子量: 518.536
• InChiKey: FMCYGTVHKAOLAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  37
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  75.2
• 氢给体数：
  0
• 氢受体数：
  9

文献信息

• Carboxamide Compounds and Their Use
  申请人：Ben-Zeev Efrat

  公开号：US20100324035A1

  公开（公告）日：2010-12-23

  Chemokine receptor antagonists, in particular, compounds of Formula (I-A) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.

  化学因子受体拮抗剂，特别是化合物式(I-A)的拮抗剂，作为化学因子CCR2受体的拮抗剂，包括其药物组合物和用途，用于治疗或预防与单核细胞聚集、淋巴细胞聚集或白细胞聚集相关的疾病。
• [EN] DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS<br/>[FR] DIHYDRONAPHTYRIDINYLE ET COMPOSÉS APPARENTÉS UTILISABLES DANS LE CADRE DU TRAITEMENT DE TROUBLES OPHTALMOLOGIQUES
  申请人：CYTOPATHFINDER INC

  公开号：WO2010129843A1

  公开（公告）日：2010-11-11

  The invention provides methods of using dihydronaphthyridinyl and related compounds to treat ophthalmological disorders, such as, wet age-related macular degeneration, diabetic retinopathy, and high myopia. Pharmaceutical compositions and methods of synthesizing the dihydronaphthyridinyl and related compounds are provided.

  这项发明提供了使用二氢萘啉基和相关化合物治疗眼科疾病的方法，如湿性年龄相关性黄斑变性、糖尿病视网膜病变和高度近视。还提供了制备二氢萘啉基和相关化合物的药物组合物和合成方法。
• DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS
  申请人：Jones Simon

  公开号：US20100286136A1

  公开（公告）日：2010-11-11

  The invention provides methods of using dihydronaphthyridinyl and related compounds to treat opthalmological disorders, such as, wet age-related macular degeneration, diabetic retinopathy, and high myopia. Pharmaceutical compositions and methods of synthesizing the dihydronaphthyridinyl and related compounds are provided.

  本发明提供了使用二氢萘啶和相关化合物治疗眼科疾病的方法，例如湿性年龄相关性黄斑变性，糖尿病视网膜病变和高度近视。还提供了制备二氢萘啶和相关化合物的药物组合物和合成方法。
• CARBOXAMIDE COMPOUNDS AND THEIR USE AS CHEMOKINE RECEPTOR AGONISTS
  申请人：CytoPathfinder, Inc.

  公开号：EP2280766A1

  公开（公告）日：2011-02-09
• US8569282B2
  申请人：——

  公开号：US8569282B2

  公开（公告）日：2013-10-29